|View printer-friendly version|
|BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS|
HACKENSACK, N.J. and PETACH TIKVA,
UCI has become the third medical center to enter into a clinical trial agreement with BrainStorm to enroll patients in the planned Phase 3 study for NurOwn. Mass.
"We are privileged to have UCI and Dr. Goyal join our pivotal Phase 3 study of NurOwn," said
"NurOwn is a very promising treatment with compelling Phase 2 data in patients with ALS; we look forward to further advancing it in clinical development and confirming the therapeutic benefit with Brainstorm," said Dr.
UCI is also part of the Alpha Stem Cells Clinics Network, which is funded by the
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-announces-agreement-with-university-of-california-irvine-medical-center-to-participate-in-phase-3-trial-of-nurown-in-als-300493500.html